An Amphiphilic Mimotope Vaccine to Enhance FDA-Approved Anti-CD19 CAR T Therapy
Exclusively Licensed
Invention type: Technology
/
Case number: #22096H
The disclosure features chimeric antigen receptor (CAR) ligands, methods for making the same, and immunomodulatory compositions comprising the CAR ligands. The disclosure also features compositions and methods of using the immunomodulatory compositions, for example, to stimulate activation of CAR expressing cells.
Researchers
Darrell J Irvine
/
Benjamin Cossette
/
Leyuan Ma
/
Naveen Mehta
/
Karl Dane Wittrup
Departments: Department of Chemical Engineering
Technology Areas: Biotechnology: Biomanufacturing, Synthetic Biology / Therapeutics: Proteins & Antibodies, Vaccines
Impact Areas: Healthy Living
-
chimeric antigen receptor-targeting ligands and uses thereof
United States of America | Published application
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.